c-Kit Inhibitors

The c-Kit receptor, also known as CD117 or stem cell factor (SCF) receptor, is a member of the Type III receptor tyrosine kinase (RTK) family, which also includes PDGFR and FLT3. It plays a critical role in the development and maintenance of hematopoietic stem cells, mast cells, melanocytes, and the interstitial cells of Cajal in the gastrointestinal tract. Upon binding to its ligand, SCF, c-Kit undergoes dimerization and autophosphorylation, creating docking sites for signaling proteins containing SH2 domains. This activates several downstream pathways, including the PI3K/Akt/mTOR pathway for cell survival, the Ras/Raf/MEK/ERK pathway for proliferation, and the JAK/STAT and Src kinase pathways for various cellular functions. Pathogenic activation of c-Kit, often through gain-of-function mutations, is a primary driver in several diseases, most notably gastrointestinal stromal tumors (GIST), systemic mastocytosis (SM), and certain subsets of acute myeloid leukemia (AML) and mucosal melanoma. The pharmacological inhibition of c-Kit has revolutionized the treatment of GIST.

Inhibitors are typically classified by their binding mode. Type I inhibitors bind to the active conformation of the kinase domain, while Type II inhibitors, such as imatinib, bind to the inactive conformation. Imatinib was the first TKI approved for GIST, targeting the ATP-binding site of the BCR-ABL, c-Kit, and PDGFR kinases. While highly effective against common exon 11 and exon 9 mutations, resistance often develops due to secondary mutations in the ATP-binding pocket (exons 13 and 14) or the activation loop (exons 17 and 18). This led to the development and approval of second-line (sunitinib) and third-line (regorafenib) therapies, which are multi-kinase inhibitors with broader activity profiles. More recently, ripretinib was approved as a switch-control inhibitor that stabilizes the kinase in an inactive state, providing a broader spectrum of activity against various c-Kit mutations.

Another significant advancement is the approval of avapritinib, a potent and selective inhibitor designed to target the D816V mutation in the activation loop, which is the primary driver of systemic mastocytosis and is notoriously resistant to imatinib. Research progress continues with the development of next-generation inhibitors that aim to minimize off-target toxicities, such as myelosuppression and skin depigmentation, which result from the inhibition of wild-type c-Kit in healthy tissues. Furthermore, combination therapies involving c-Kit inhibitors and immunotherapies or other targeted agents are being explored to enhance durable responses. Key research tool compounds like masitinib are also being investigated for inflammatory and neurodegenerative conditions, expanding the potential applications of c-Kit modulation beyond oncology. The main challenge in the field remains the heterogeneity of resistance mutations, necessitating a personalized approach to treatment where the choice of inhibitor is guided by the specific mutational profile of the patient's tumor. This precision medicine approach is increasingly supported by liquid biopsy techniques to monitor the emergence of resistance mutations in real-time.